Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract
A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002) Read Moreabout Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract
Phase: II/III
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
Phase: II/III
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301) Read Moreabout Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
Phase: III
Ph3 HR+/HER2- BC (OVELIA)
A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA) Read Moreabout Ph3 HR+/HER2- BC (OVELIA)
Phase: III
Ph3 HER2+/ER+ BC
A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571) Read Moreabout Ph3 HER2+/ER+ BC
Phase: III
Ph3 Sac Gov Pemb vs PC BC (ASCENT-04)
A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (GS-US-592-6173) Read Moreabout Ph3 Sac Gov Pemb vs PC BC (ASCENT-04)
Phase: III
Ph3 Sac GOv vs PC BC (ASCENT-03)
A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238) Read Moreabout Ph3 Sac GOv vs PC BC (ASCENT-03)
Phase: III
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001) Read Moreabout Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase: III
Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02)
D926PC00001: A Phase III Open-label Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02). Read Moreabout Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02)
Phase: III
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH) Read Moreabout Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
Phase: III
Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)
GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD) Read Moreabout Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)
Phase: III
INCMGA00012 Endo Cancer
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204) Read Moreabout INCMGA00012 Endo Cancer
Phase: II
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
Phase: II
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
Phase: III
Ph2 ONC-392 Pembro Ovarian PROC (PRESERVE-004)
Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients with Platinum Resistant Ovarian Cancer (PROC) (PRESERVE-004 MK-3475-E24 GOG-3081) Read Moreabout Ph2 ONC-392 Pembro Ovarian PROC (PRESERVE-004)
Phase: II
PH2 Brentux+CHP In Tx Naive PTCL
A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032) Read Moreabout PH2 Brentux+CHP In Tx Naive PTCL
Phase: II
STAR: Zanu in Acala intolerant B-Cell
A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell
Phase: II
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004 Read Moreabout STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
Phase: III
Ph2 MRTX849 Pembro NSCLC KRAS
A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007) Read Moreabout Ph2 MRTX849 Pembro NSCLC KRAS
Phase: II/III
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777) Read Moreabout STAR: PH1/3 Biomarker unresectable stg3 NSCLC
Phase: III
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX) Read Moreabout STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
Phase: III
Ph3 Study of AK112 or Placebo + Pemtrexed & Carboplatin EGFR NSCLC
A Randomized Double-blind Multi-center Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi) (AK112-301) Read Moreabout Ph3 Study of AK112 or Placebo + Pemtrexed & Carboplatin EGFR NSCLC
Phase: III
Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor
A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216) Read Moreabout Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor
Phase: III
Ph3 SGN-B6A vs docetaxel NSCLC
A randomized phase 3 open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (SGN-B6A-002) Read Moreabout Ph3 SGN-B6A vs docetaxel NSCLC
Phase: III
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
Phase: II/III
Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)
D9103C00001: A Phase III Randomized Placebo-controlled Double-blind Multi-center International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Read Moreabout Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)
Phase: III
Biomarker status NSCLC
MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361) Read Moreabout Biomarker status NSCLC
PH2 Brentux+CHP In Tx Naive PTCL
A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032) Read Moreabout PH2 Brentux+CHP In Tx Naive PTCL
Phase: II
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302) Read Moreabout Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
Phase: I
STAR: Zanu in Acala intolerant B-Cell
A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell
Phase: II
Ph2 Epco r/r B-Cell Lymph out pt
A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362) Read Moreabout Ph2 Epco r/r B-Cell Lymph out pt
Phase: II
Ph2 Sub Mosunetuzumab B-cell malig
AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389) Read Moreabout Ph2 Sub Mosunetuzumab B-cell malig
Phase: II
Ph2 SKB264 + Pembro in Select Solid Tumors
A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06) Read Moreabout Ph2 SKB264 + Pembro in Select Solid Tumors
Phase: II
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
Phase: II
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
Phase: III
Ph2 ONC-392 Pembro Ovarian PROC (PRESERVE-004)
Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients with Platinum Resistant Ovarian Cancer (PROC) (PRESERVE-004 MK-3475-E24 GOG-3081) Read Moreabout Ph2 ONC-392 Pembro Ovarian PROC (PRESERVE-004)
Phase: II
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
Phase: II
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
Phase: III
Ph2 ONC-392 Pembro Ovarian PROC (PRESERVE-004)
Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients with Platinum Resistant Ovarian Cancer (PROC) (PRESERVE-004 MK-3475-E24 GOG-3081) Read Moreabout Ph2 ONC-392 Pembro Ovarian PROC (PRESERVE-004)
Phase: II
Ph2 SKB264 + Pembro in Select Solid Tumors
A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06) Read Moreabout Ph2 SKB264 + Pembro in Select Solid Tumors
Phase: II
PH3 Place Capi+ Doce Place+ Doce mCRPC
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001) Read Moreabout PH3 Place Capi+ Doce Place+ Doce mCRPC
Phase: III
STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007) Read Moreabout STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
Phase: II